Home
Back
| Risk Level | Score Range | Risk of Major Bleeding (%) |
|---|---|---|
| Very Low | <21 | 3.1 |
| Low | 21-30 | 5.5 |
| Medium | 31-40 | 8.6 |
| High | 41-50 | 11.9 |
| Very High | >50 | 19.5 |
*Definition of major bleeding: intracranial bleeding, retroperitoneal bleeding, HCT drop ≥12%, or requiring blood transfusion.
Bleeding is one of the primary adverse events to be assessed in patients with NSTE-ACS, and its incidence is positively correlated with long-term prognosis. Reducing the incidence of in-hospital bleeding is also one of the primary tasks for clinicians.
The GRACE score and TIMI score are currently the two most popular methods for bleeding risk assessment. The GRACE score can accurately assess the in-hospital bleeding risk of patients, but it is complicated to calculate and requires computer and software support. The TIMI score is relatively simple to calculate, but its predictive accuracy is not as good as the GRACE score.
The 2011 ESC guidelines for the treatment of NSTE-ACS recommend using the CRUSADE score to assess patients' long-term prognosis and bleeding risk. This scoring system is derived from the results of the CRUSADE cohort registry study, which analyzed the correlation between baseline data and bleeding events in 71,277 patients and was validated in 17,857 patients.
Compared with the GRACE and TIMI scores, the CRUSADE score combines the accuracy of both with ease of use.
